Fundraising FoxOrbiMed — 2021 Investments
21 investments dated 2021 · listed companies and verified rows first · show all
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Benjamin Oakes(Founder)inJennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)Brett Staahl(Founder)
Co-investorsAndreessen HorowitzAvoro Capital AdvisorsMenlo VenturesRA CapitalWellington ManagementSanofi Ventures
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life SciencesHercules Capital, Inc.+8 more
Invivyd is a biopharmaceutical company that develops antibody-based product candidates for the prevention and treatment of serious viral infectious diseases, combining viral surveillance and predictive modeling with antibody engineering.
BiotechHealthtechWaltham, US
Tillman U. Gerngross(Executive Officer, Director)Marc Elia(Founder)inLynn Connolly(Executive Officer)inEric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)inRebecca Dabora(Executive Officer)in
Co-investorsBain Capital Life SciencesForesite CapitalGV (Google Ventures)MRL Ventures FundPremji InvestRA Capital+6 more
ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.
BiotechHealthtechMedical DevicesSan Diego, US
Zhen Li(Co-founder, President & CEO)inRui Zhu(Founding Member & Chief Technology Officer)Rob Ackles(Chief People Officer)inRyan Fisk(Chief Financial Officer & Chief Business Officer)inRobert A. MacLeod(Chief Scientific Officer)inChristopher Claeboe(Senior Vice President of Operations)in
Co-investorsBain Capital Life SciencesSR One Capital ManagementLilly Asia VenturesT. Rowe PriceAscenta CapitalHBM Healthcare Investments+4 more
i2020 Accelerator (T123 LLC) is a drug discovery accelerator that de-risks early-stage science and advances drug discovery platforms toward lead and clinical candidate stage within roughly two years, working across therapeutic areas such as oncology, immunology, and infectious diseases.
BiotechDeep TechHealthtechSan Diego, US
Co-investorsTorrey Pines InvestmentBioGeneration VenturesBGV
Variantyx is a molecular diagnostics company offering genetic testing for rare genetic disorders, reproductive genetics, and precision oncology.
AI & Machine LearningBiotechDigital HealthHealthtechFramingham, US
Haim Neerman(Co-founder)inTomer Jackman(Co-founder & VP Customer Support and Lab Services)inJeffrey Weisberg(Chief Financial Officer)inYaron Rachmany(Operations, R&D, IT (executive))inChristine Stanley(Chief Genomics and Compliance Officer)inEyal Reinstein(Chief Medical Officer)in
Co-investors20/20 HealthCare Partners LLCBosch VenturesNew Era Capital PartnersPeregrine VenturesPitangoQuark Venture Inc.+2 more
Chemomab is a clinical-stage biotech developing therapies that target the CCL24 cytokine involved in fibro-inflammatory diseases, with its lead antibody nebokitug tested in conditions including primary sclerosing cholangitis, systemic sclerosis, MASH and idiopathic pulmonary fibrosis.
BiotechHealthtechTel Aviv
Adi Mor(Executive Officer, Director)inAdi Mor George(Executive Officer, Director)Jill Quigley(Director)inSigal Fattal(Executive Officer)inMatthew Frankel(Executive Officer)inArnon Aharon(Executive Officer)in
Board seatStephen Squinto· per SEC Form D
Co-investorsAltium CapitalSBI JI Innovation Advisory Ltd.
Genetic medicines company developing targeted nucleic acid therapeutics via a gene monoclonal antibody platform.
BiotechPennington, US
Chris Duke(Mr. Duke is the Chief Operating Officer of the Issuer.)inDale Ludwig(Mr. Ludwig is the Chief Scientific Officer)inAnuj Goswami(Mr. Goswami is the General Counsel and Secretary)inClaudine Prowse(Ms. Prowse is the Chief Financial Officer)inGary Sender(Director)Julie Hambleton(Director)
Board seatChau Khuong· per SEC Form D
Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)inJAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)inPAUL ROGERS(Executive Officer)in
BoardDAVID ALLISON(Director)in
Board seatKevin KochKlaus Veitinger· per SEC Form D
Co-investors5AM VenturesSamsara BioCapitalvenBio PartnersVivo CapitalRTW Investments L.P.venBio Global Strategic+1 more
Noctrix Health develops clinically validated wearable therapeutics for managing chronic neurological disorders, with its first product Nidra receiving FDA De Novo authorization and dedicated CMS HCPCS codes.
Digital HealthMedical DevicesWellness & FitnessPleasanton, US
Shri Raghunathan(Founder)inShriram Raghunathan(Executive Officer, Director)
BoardAllan May(Director)Mudit Jain(Director)inTracy Pappas(Director)in
Board seatChau Khuong· per SEC Form D
Co-investorsAngelini VenturesBlue Venture FundsJoyance PartnersTreo Ventures, LlcZühlke VenturesBridge Bank+2 more
Vanqua Bio is a biotechnology company developing molecules intended to become medicines for neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and related neurological conditions.
BiotechDeep TechHealthtechLongevityChicago, US
Rand Sutherland(Director)inJim Sullivan(CEO)inKevin Hunt(CSO)in
BoardBernard Davitian(Director)Uya Chuluunbaatar(Director)
Board seatJonathan SilversteinStephen SquintoMona Ashiya· per SEC Form D
Co-investorsAvoro Capital AdvisorsOUP (Osage University Partners)Pontifax Venture CapitalCasdin CapitalOmega Funds
BiotechSeattle, US
Mitchell Gold(Executive Chairman and Chief Executive Officer)inMichael Kornacker(Executive Officer, Director)inRyan Swanson(Executive Officer, Director)inDavid Miller(Executive Officer, Director)inJames Paul Rickey(Senior Vice President and Chief Financial Officer)Mark James Litton(President and Chief Operating Officer)
Co-investorsDecheng CapitalFrazier Life SciencesBiotechnology Value Fund
Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic.
AI & Machine LearningBiotechDeep TechSan Diego, US
Eric A. Murphy(Executive Officer, Director, Promoter)inRyan B. Corcoran(Director, Promoter)Richard Heyman(Founder)
BoardThilo Schroeder(Director)inCarl Gordon(Director)inArjun Goyal(Director)in
Co-investorsCanaan PartnersNextech InvestVida VenturesDigitalis VenturesNVIDIA
binx health develops FDA-cleared, CLIA-waived point-of-care diagnostic testing for chlamydia and gonorrhea in male and female patients, delivering central-lab-quality results in about thirty minutes so patients can test, get diagnosed, and receive treatment in one visit.
BiotechDigital HealthHealthtechMedical DevicesTrowbridge
Anna Dixon(Executive Officer)inMarc Jones(Executive Officer)inJeffrey R. Luber(Executive Officer, Director)in
BoardAndrew Goldman(Director)Martin Munchbach(Director)Jihua Wang(Director)
Co-investorsAsabys Partners
Carrot provides fertility benefits that companies of any size offer to employees, covering services such as egg freezing, infertility treatments including IVF, and LGBT+ conception.
Digital HealthFemTechHealthtechHR TechSan Francisco, US
Asima Ahmad(CMO)inTammy Sun(CEO, co-founder)inDavid Utley(Executive Officer, Director)Dr. Asima Ahmad(Founder)Arun VenkatesanMaxwell Radomsky
Co-investors515 VenturesAll TurtlesAurumBackstage CapitalCore Venture CapitalCRV (Charles River Ventures)+18 more
Janux Therapeutics is a clinical-stage biotech company developing precision-engineered immunotherapies for the treatment of cancer and autoimmune diseases.
BiotechDeep TechHealthtechMedical DevicesLa Jolla, US
David Campbell, Ph.D.(Executive Officer, Director)inTighe Reardon(Executive Officer)
BoardJay Lichter, Ph.D.(Director)Jake Simson, Ph.D.(Director)Peter Thompson, M.D.(Director)inStefan Heller(Director)
Co-investorsAvalon BioVenturesSamsara BioCapital
Kumquat Biosciences is a biotech company developing small-molecule cancer therapeutics, combining drug discovery and clinical expertise to advance new oncology treatments.
BiotechSan Diego, US
Yi Liu(Executive Officer, Director)inYi Liu, Ph.D.(CEO)Lynn Yang(Director)
BoardCarl Gordon(Director)in
Co-investorsEcoR1 CapitalRoche Venture Fund
Developing off-the-shelf hematopoietic stem cell therapies for severe diseases.
Co-investorsAisling CapitalNorthpond Ventures
Theseus builds robotic situational awareness software using visual positioning for drones that operate in GPS-denied environments.
Advanced ManufacturingAI & Machine LearningDefense TechHardwareRoboticsSan Francisco, US
Ian Laffey(Founder)inSacha Lévy(Founder)inCarl Schoeller(Founder)Yasmin Acevedo(Recruiter)Luca Lery Moffat(COO)
Co-investorsY CombinatorFirst Round CapitalPioneerAntlerEndor CapitalForesite Capital+7 more
vVARDIS develops biomimetic, non-invasive dental products based on P11-4 peptide technology to treat early-stage tooth decay by regenerating enamel without drilling.
BiotechHealthtechMedical DevicesBaar, CH
GOLNAR ABIVARDI-SIGNER(Director)HALEH ABIVARDI-BRONNER(Director)Haley Abivardi(Co-founder, DMD)inGoly Abivardi(Co-founder, DMD)in
BoardFLORIAN RANDLKOFER(Director)GERARDUS ADRIANUS HOOGLAND(Director)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.